Care Access is a leading Decentralized Research Organization (DRO) that breaks down traditional barriers in clinical research and is taking steps to make clinical studies more accessible, representative, and inclusive for people of all backgrounds. We actively partner with many communities that are traditionally left out of the clinical trial process. Care Access has partnered with pharmaceutical company Pfizer to research on the development of a preventative Lyme Disease vaccine. The purpose of this study is to learn if the developing vaccine is safe and effective in preventing Lyme disease in adults and children ages 5 years of age and older. The study will last about 2 years, during that time participants will receive 3 doses of the vaccine or placebo followed by a booster dose 1 year later. Care Access wants to spread the word about the research study, as well as help members of the community prevent Lyme Disease.